Clinical Course After Radical Local Therapy for Oligo-Recurrence of Nonsmall Cell Lung Cancer.

IF 2 3区 医学 Q3 ONCOLOGY
Dai Sonoda, Raito Maruyama, Yasuto Kondo, Shunsuke Mitsuhashi, Satoru Tamagawa, Masahito Naito, Masashi Mikubo, Kazu Shiomi, Yukitoshi Satoh
{"title":"Clinical Course After Radical Local Therapy for Oligo-Recurrence of Nonsmall Cell Lung Cancer.","authors":"Dai Sonoda, Raito Maruyama, Yasuto Kondo, Shunsuke Mitsuhashi, Satoru Tamagawa, Masahito Naito, Masashi Mikubo, Kazu Shiomi, Yukitoshi Satoh","doi":"10.1002/jso.28032","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Radical local therapy is effective for oligo-recurrence of non-small cell lung cancer (NSCLC). We retrospectively assessed patients with oligo-recurrent NSCLC and detailed the clinical course after radical local therapy.</p><p><strong>Methods: </strong>We analyzed 1028 patients who underwent complete resection for NSCLC. We defined oligo-recurrence as up to two metachronous recurrences, radical local therapy as local therapy performed with curative intent, and progressive disease as the appearance of new lesions/re-enlargement of the initial recurrence sites.</p><p><strong>Results: </strong>Of the 132 patients who developed oligo-recurrence, 88 received radical local therapy. Fifty-eight patients had progressive disease. Fifteen patients remained cancer free for > 5 years. Epidermal growth factor receptor (EGFR) positivity was associated with disease progression (odds ratio, 3.90; p = 0.025). Active treatment for disease progression (hazard ratio, 2.54; p = 0.012) and the absence of re-enlarged lesions at sites of radical local therapy for recurrence (hazard ratio, 2.32; p = 0.031) were associated with prolonged post-recurrence overall survival.</p><p><strong>Conclusions: </strong>Patients with EGFR mutations who develop oligo-recurrence should be monitored for disease progression. Re-enlargement of lesions after radical local therapy was associated with a poor prognosis. A good prognosis can be expected with active treatment, even in the event of disease progression.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.28032","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: Radical local therapy is effective for oligo-recurrence of non-small cell lung cancer (NSCLC). We retrospectively assessed patients with oligo-recurrent NSCLC and detailed the clinical course after radical local therapy.

Methods: We analyzed 1028 patients who underwent complete resection for NSCLC. We defined oligo-recurrence as up to two metachronous recurrences, radical local therapy as local therapy performed with curative intent, and progressive disease as the appearance of new lesions/re-enlargement of the initial recurrence sites.

Results: Of the 132 patients who developed oligo-recurrence, 88 received radical local therapy. Fifty-eight patients had progressive disease. Fifteen patients remained cancer free for > 5 years. Epidermal growth factor receptor (EGFR) positivity was associated with disease progression (odds ratio, 3.90; p = 0.025). Active treatment for disease progression (hazard ratio, 2.54; p = 0.012) and the absence of re-enlarged lesions at sites of radical local therapy for recurrence (hazard ratio, 2.32; p = 0.031) were associated with prolonged post-recurrence overall survival.

Conclusions: Patients with EGFR mutations who develop oligo-recurrence should be monitored for disease progression. Re-enlargement of lesions after radical local therapy was associated with a poor prognosis. A good prognosis can be expected with active treatment, even in the event of disease progression.

非小细胞肺癌寡复发局部根治术后的临床表现
背景和目的:根治性局部治疗对低复发非小细胞肺癌(NSCLC)有效。我们对少复发 NSCLC 患者进行了回顾性评估,并详细分析了根治性局部治疗后的临床过程:我们分析了 1028 例接受完全切除术的 NSCLC 患者。我们将寡复发定义为最多两次异次元复发,将根治性局部治疗定义为以治愈为目的的局部治疗,将疾病进展定义为出现新病灶/初始复发部位再次扩大:结果:在132名出现寡复发的患者中,88人接受了根治性局部治疗。58名患者的病情有所进展。15名患者保持无癌状态超过5年。表皮生长因子受体(EGFR)阳性与疾病进展有关(几率比3.90;P = 0.025)。积极治疗疾病进展(危险比为2.54;p = 0.012)和根治性局部治疗复发部位无再次扩大病灶(危险比为2.32;p = 0.031)与复发后总生存期延长有关:结论:表皮生长因子受体(EGFR)突变患者若出现寡复发,应监测疾病进展情况。结论:表皮生长因子受体突变患者出现寡复发时,应监测疾病的进展情况。通过积极治疗,即使出现疾病进展,也可望获得良好的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.70
自引率
4.00%
发文量
367
审稿时长
2 months
期刊介绍: The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信